The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer
Open accessAbstract
Antibodies targeting the programmed cell death protein 1/programmed death-ligand 1 (PD-L1) interaction have shown clinical activity in multiple cancer types. PD-L1 protein expression is a clinically validated predictive biomarker of response for such therapies. Prior studies evaluating the expression of PD-L1 in primary prostate cancers have reported highly variable rates of PD-L1 positivity. In addition, limited data exist on PD-L1 expression in metastatic castrate-resistant prostate cancer (mCRPC). Here, we determined PD-L1 protein expression by immunohistochemistry using a validated PD-L1-specific antibody (SP263) in a large and representative cohort of primary prostate cancers and prostate cancer metastases. The study included 539 primary prostate cancers comprising 508 acinar adenocarcinomas, 24 prostatic duct adenocarcinomas, 7 small-cell carcinomas, and a total of 57 cases of mCRPC. PD-L1 positivity was low in primary acinar adenocarcinoma, with only 7.7% of cases showing detectable PD-L1 staining. Increased levels of PD-L1 expression were noted in 42.9% of small-cell carcinomas. In mCRPC, 31.6% of cases showed PD-L1-specific immunoreactivity. In conclusion, in this comprehensive evaluation of PD-L1 expression in prostate cancer, PD-L1 expression is rare in primary prostate cancers, but increased rates of PD-L1 positivity were observed in mCRPC. These results will be important for the future clinical development of programmed cell death protein 1/PD-L1-targeting therapies in prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Integrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
Self-citationAR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315815 · Cited by 2,710
Self-citationThe mutational landscape of lethal castration-resistant prostate cancer
Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., et al. (2012) · Nature · doi:10.1038/nature11125 · Cited by 2,517 · cited 2×
“In brief, raw data for GSE35988 22 and processed data for Stand Up To Cancer metastatic prostate cancer 23 were obtained from Gene Expression Omnibus ( https://www.ncbi.nlm.nih.gov/geo ) and cBioPortal version 1.12.1 24 ( http://www.cbioportal.org ), respectively, and processed as previously…”
MethodInfluentialSelf-citationReinhold, W. C., Sunshine, M., Liu, H., Varma, S., Kohn, K. W., Morris, J., Doroshow, J., & Pommier, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1370 · Cited by 887
Cited by
Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study
Hansen, A. R., Massard, C., Ott, P. A., Haas, N. B., Lopez, J. S., Ejadi, S., Wallmark, J. M., Keam, B., Delord, J.-P., Aggarwal, R., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy232 · Cited by 363
Brady, L., Kriner, M., Coleman, I., Morrissey, C., Roudier, M., True, L. D., Gulati, R., Plymate, S. R., Zhou, Z., Birditt, B., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21615-4 · Cited by 297
Powles, T., Yuen, K. C., Gillessen, S., Kadel, E. E., Rathkopf, D., Matsubara, N., Drake, C. G., Fizazi, K., Piulats, J. M., Wysocki, P. J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01600-6 · Cited by 256
Self-citationThe efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives
Majidpoor, J., & Mortezaee, K. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108707 · Cited by 236
Metadata
- Authors
- Haffner, M. C., Guner, G., Taheri, D., Netto, G. J., Palsgrove, D. N., Zheng, Q., Guedes, L. B., Kim, K., Tsai, H., Esopi, D. M., Lotan, T. L., Sharma, R., Meeker, A. K., Chinnaiyan, A. M., Nelson, W. G., Yegnasubramanian, S., Luo, J., Mehra, R., Antonarakis, E. S., Drake, C. G., & De Marzo, A. M.
- Venue
- The American Journal of Pathology
- Publisher
- Elsevier BV
- Published
- 2018-06
- Volume
- 188
- Issue
- 6
- Pages
- 1478-1485
- ISSN
- 0002-9440 (ISSN-L)
- OpenAlex
- W2791357477
- Cited by
- 159
- References
- 9
- FWCI
- 6.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer. https://app.cochat.ai/papers/10.1016/j.ajpath.2018.02.014
- The paper
- Haffner, M. C., Guner, G., Taheri, D., Netto, G. J., Palsgrove, D. N., Zheng, Q., Guedes, L. B., Kim, K., Tsai, H., Esopi, D. M., Lotan, T. L., Sharma, R., Meeker, A. K., Chinnaiyan, A. M., Nelson, W. G., Yegnasubramanian, S., Luo, J., Mehra, R., Antonarakis, E. S., . . . De Marzo, A. M. (2018). Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer. The American Journal of Pathology. https://doi.org/10.1016/j.ajpath.2018.02.014
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.